Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Using CRISPR to enhance T cell effector function for therapeutic applications
Julian J. Freen‐van Heeren
Cytokine X (2020) Vol. 3, Iss. 1, pp. 100049-100049
Open Access | Times Cited: 21

Showing 21 citing articles:

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
Yanxin Xu, Chen Chen, Yaxin Guo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 33
Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity
Jonaid Ahmad Malik, Gurpreet Kaur, Javed N. Agrewala
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127252-127252
Open Access | Times Cited: 17
Application of novel CAR technologies to improve treatment of autoimmune disease
Abigail Cheever, Chloe C. Kang, Kim L. O’Neill, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Engineered T cells and their therapeutic applications in autoimmune diseases
Lei Bao, Xiaochen Bo, Huai-Wen Cao, et al.
动物学研究 (2022) Vol. 43, Iss. 2, pp. 150-165
Open Access | Times Cited: 19
The Cellular and Molecular Immunotherapy in Prostate Cancer
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, D. S. Prabakaran, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1370-1370
Open Access | Times Cited: 16
Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV
Julian J. Freen‐van Heeren
BioTech (2022) Vol. 11, Iss. 3, pp. 25-25
Open Access | Times Cited: 15
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Györgyi Műzes, Ferenc Sípos
Cells (2023) Vol. 12, Iss. 11, pp. 1534-1534
Open Access | Times Cited: 9
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Peter L. Smith, Katarzyna Piadel, Angus Dalgleish
Vaccines (2021) Vol. 9, Iss. 12, pp. 1392-1392
Open Access | Times Cited: 15
Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response
Yosef Tsegaye Dabi, Andualem Henok, Sisay Teka Degechisa, et al.
Biologics (2022) Vol. Volume 16, pp. 35-45
Open Access | Times Cited: 10
Molecular and therapeutic effect of CRISPR in treating cancer
Sawani Rodrigo, Kaveesha Senasinghe, Sameer Quazi
Medical Oncology (2023) Vol. 40, Iss. 2
Open Access | Times Cited: 5
The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes
Chirine Rafia, Clément Loizeau, Ophélie Renoult, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 5
Clinical trials aimed at HIV cure or remission: new pathways and lessons learned
Maya Dyveke Schou, Ole S. Søgaard, Thomas A. Rasmussen
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 11, pp. 1227-1243
Closed Access | Times Cited: 5
Toll‐like receptor‐2/7‐mediated T cell activation: An innate potential to augment CD8+T cell cytokine production
Julian J. Freen‐van Heeren
Scandinavian Journal of Immunology (2020) Vol. 93, Iss. 5
Open Access | Times Cited: 12
Post‐transcriptional control of T‐cell cytokine production: Implications for cancer therapy
Julian J. Freen‐van Heeren
Immunology (2021) Vol. 164, Iss. 1, pp. 57-72
Open Access | Times Cited: 10
Addressing HIV‐1 latency with Flow‐FISH: Finding, characterizing and targeting HIV‐1 infected cells
Julian J. Freen‐van Heeren
Cytometry Part A (2021) Vol. 99, Iss. 9, pp. 861-865
Closed Access | Times Cited: 5
Ten Years of CRISPRing Cancers In Vitro
Davide Capoferri, Serena Filiberti, Jessica Faletti, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5746-5746
Open Access | Times Cited: 3
Employing CRISPR-Cas9 to Enhance T Cell Effector Function
Julian J. Freen‐van Heeren
Methods in molecular biology (2024), pp. 195-208
Closed Access
CLASH of the Titans: How CAR-T Cells Can Triumph Over Tumors
Rianne Opstelten, Julian J. Freen‐van Heeren
The CRISPR Journal (2023) Vol. 6, Iss. 2, pp. 87-89
Closed Access | Times Cited: 1
Exploiting HIV‐1 tropism to target CD4+ T cells for CRISPR
Julian J. Freen‐van Heeren
Immunology and Cell Biology (2021) Vol. 99, Iss. 7, pp. 677-679
Open Access | Times Cited: 2
Combining CRISPR with Flow‐FISH to study CRISPR‐mediated genome perturbation
Julian J. Freen‐van Heeren
Cytometry Part A (2023) Vol. 105, Iss. 1, pp. 7-9
Open Access
A dramatic impairment of the antitumor activity of human Vγ9Vδ2 T cells is induced by TGF-β through significant phenotype, transcriptomic and metabolic changes
Chirine Rafia, Clément Loizeau, Ophélie Renoult, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top